News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Sep 13, 2022

Summary Toggle aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation for systemic sclerosis (SSc). SAN DIEGO , Sept. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the
Sep 9, 2022

Summary Toggle aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th

SAN DIEGO – September 9, 2022 – aTyr Pharma, Inc. (Nasdaq: LIFE) (the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Ashlee Dunston, Director of Investor Relations and
Sep 6, 2022

Summary Toggle aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
Sep 1, 2022

Summary Toggle aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022

SAN DIEGO , Sept. 01, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present a poster on Monday, September
Aug 15, 2022

Summary Toggle aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

First sites initiated in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis. FDA granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. Ended the second quarter 2022 with $89.3 million in cash, restricted cash, cash equivalents and investments.
Aug 12, 2022

Summary Toggle aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , Aug. 12, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on its proprietary tRNA synthetase biology platform, today announced that the Compensation Committee of aTyr’s Board of
Aug 11, 2022

Summary Toggle aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

Company is investigating efzofitimod in global pivotal Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis patients SAN DIEGO , Aug. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development
Aug 4, 2022

Summary Toggle aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

Management to host conference call and webcast on August 15th at 5:00 pm EDT / 2:00 pm PDT SAN DIEGO , Aug. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
Jun 14, 2022

Summary Toggle aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

Poster to be presented at the Keystone Symposia on Tissue Fibrosis and Repair. Second tRNA synthetase receptor identified from company’s platform. Findings suggest AARS fragment may have therapeutic potential in fibrosis, inflammation and cancer. SAN DIEGO , June 14, 2022 (GLOBE NEWSWIRE) -- aTyr
Jun 13, 2022

Summary Toggle aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

Conference hosted by The Ohio State University’s Center for RNA Biology to showcase latest advancements in tRNA biology SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from